Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system

Future Cardiology

Volumn 9, Issue 1, 2013, Pages 23-38

  Clarke, Carolyn ^a   Flores Muñoz, Monica ^a   McKinney, Clare A ^a   Milligan, Graeme ^a   Nicklin, Stuart A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

angiotensin (1 7); angiotensin (1 9); angiotensin converting enzyme 2; cardiac remodeling; Mas; renin angiotensin system; vascular dysfunction

Indexed keywords

1 [[2 (DIMETHYLAMINO)ETHYL]AMINO] 4 (HYDROXYMETHYL) 7 [[(4 METHYLPHENYL) SULFONYL]OXY] 9H XANTHEN 9 ONE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN[1-10]; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; ANGIOTENSIN[1-8]; ANGIOTENSIN[1-9]; APN01; CARDIOVASCULAR AGENT; CGEN 856S; COMPOUND 21; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; IRBESARTAN; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 3; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; PHOSPHOLAMBAN; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR REMODELING; CELL MIGRATION; CELL PROLIFERATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY TUBULE ABSORPTION; MORBIDITY; NEOINTIMA; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANGIOTENSIN I; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR REMODELING;

EID: 84871596560     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.75     Document Type: Review

References (117)

1. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat. Med. 15(1), 75-83 (2009).
2. Huang F, Thompson JC, Wilson PG, Aung HH, Rutledge JC, Tannock LR. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J. Lipid Res. 49(3), 521-530 (2008).
3. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 268(33), 24539-24542 (1993).
4. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292(1), C82-C97 (2007).
5. Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Lorell BH. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 99(1), 22-25 (1999).
6. Metcalfe BL, Huentelman MJ, Parilak LD et al. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer. Hypertension 43(6), 1233-1238 (2004).
7. Yan X, Schuldt AJ, Price RL et al. Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 294(3), H1274-H1281 (2008).
8. Taguchi K, Matsumoto T, Kobayashi T. Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway. Pharmacol. Res. 66, 41-50 (2012).
9. Ohtsu H, Higuchi S, Shirai H et al. Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells. Endocrinology 149(7), 3569-3575 (2008).
10. McMurray JJ. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy? Nat. Clin. Pract. Cardiovasc. Med. 2(3), 128-129 (2005).
11. Steckelings UM, Paulis L, Unger T, Bader M. Emerging drugs which target the renin-angiotensin-aldosterone system. Expert Opin. Emerg. Dr. 16(4), 619-630 (2011).
12. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme-cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275(43), 33238-33243 (2000).
13. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87(5), E1-E9 (2000).
14. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277(17), 14838-14843 (2002).
15. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc. Res. 73(3), 463-469 (2007).
16. Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 292(6), H3019-H3024 (2007).
17. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417(6891), 822-828 (2002).
18. Kassiri Z, Zhong J, Guo D et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail. 2(5), 446-455 (2009).
19. Patel VB, Bodiga S, Fan D et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension 59(6), 1195-1203 (2012).
20. Masson R, Nicklin SA, Craig MA et al. Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2. Hypertension 53(4), 694-700 (2009).
21. Donoghue M, Wakimoto H, Maguire CT et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J. Mol. Cell Cardiol. 35(9), 1043-1053 (2003).
22. Santos RA, Simoes e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl Acad. Sci. USA 100(14), 8258-8263 (2003).
23. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108(14), 1679-1681 (2003).
24. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108(17), 2141-2146 (2003).
25. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase Life Sci. 52(18), 1461-1480 (1993).
26. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47(3), 515-521 (2006).
27. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr. Opin. Nephrol. Hypertens. 20(1), 1-6 (2011).
28. Santos RA, Campagnole-Santos MJ, Baracho NC et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res. Bull. 35(4), 293-298 (1994).
29. Nadu AP, Ferreira AJ, Reudelhuber TL, Bader M, Santos RA. Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats. J. Am. Soc. Hypertens. 2(5), 341-348 (2008).
30. Santiago NM, Guimaraes PS, Sirvente RA et al. Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 55(4), 889-896 (2010).
31. Mercure C, Yogi A, Callera GE et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res. 103(11), 1319-1326 (2008).
32. Ferreira AJ, Santos RA, Bradford CN et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55(2), 207-213 (2010).
33. Wang Y, Qian C, Roks AJ et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ. Heart Fail. 3(2), 286-293 (2010).
34. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc. Health Risk Manag. 4(4), 787-803 (2008).
35. Hsueh WA, Wyne K. Renin-angiotensin-aldosterone system in diabetes and hypertension. J. Clin. Hypertens. (Greenwich) 13(4), 224-237 (2011).
36. Patel VB, Bodiga S, Basu R et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ. Res. 110(10), 1322-1335 (2012).
37. Murca TM, Moraes PL, Capuruco CA et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul. Pept. 177(1-3), 107-115 (2012).
38. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292(1), H666-H672 (2007).
39. Yousif MH, Dhaunsi GS, Makki BM, Qabazard BA, Akhtar S, Benter IF. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol. Res. 66(3), 269-275 (2012).
40. Dias-Peixoto MF, Santos RA, Gomes ER et al. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52(3), 542-548 (2008).
41. Li Y, Wu J, He Q et al. Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertens. Res. 32(5), 369-374 (2009).
42. Giani JF, Gironacci MM, Munoz MC, Pena C, Turyn D, Dominici FP. Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol. 293(2), H1154-H1163 (2007).
43. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br. J. Pharmacol. 165(5), 1390-1400 (2012).
44. Zhang Y, Lu J, Shi J et al. Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats. Neuropeptides 42(5-6), 593-600 (2008).
45. Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol. Res. 59(4), 263-268 (2009).
46. Ocaranza MP, Lavandero S, Jalil JE et al. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J. Hypertens. 28(5), 1054-1064 (2010).
47. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 95(6), 1455-1463 (1997).
48. Jackman HL, Massad MG, Sekosan M et al. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 39(5), 976-981 (2002).
49. Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM, Chappell MC. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp. Physiol. 93(5), 613-621 (2008).
50. Ocaranza MP, Godoy I, Jalil JE et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48(4), 572-578 (2006).
51. Erdos EG, Jackman HL, Brovkovych V, Tan F, Deddish PA. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J. Mol. Cell Cardiol. 34(12), 1569-1576 (2002).
52. Marcic B, Deddish PA, Jackman HL, Erdos EG. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension 33(3), 835-843 (1999).
53. Flores-Munoz M, Smith NJ, Haggerty C, Milligan G, Nicklin SA. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J. Physiol. 589(Pt 4), 939-951 (2011).
54. Ocaranza MP, Rivera P, Novoa U et al. Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. J. Hypertens. 29(4), 706-715 (2011).
55. Flores-Munoz M, Work LM, Douglas K et al. Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 59(2), 300-307 (2012).
56. Yan X, Price RL, Nakayama M et al. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 285(5), H2179-H2187 (2003).
57. D'amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46(6), 1347-1354 (2005).
58. Bosnyak S, Widdop RE, Denton KM, Jones ES. Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int. J. Hypertens. 2012, 192567 (2012).
59. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45(5), 960-966 (2005).
60. Hamming I, Timens W, Bulthuis MI, Lely AT, Navis GJ, Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203(2), 631-637 (2004).
61. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 289(3), H1013-H1019 (2005).
62. Sluimer JC, Gasc JM, Hamming I et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J. Pathol. 215(3), 273-279 (2008).
63. Lovren F, Pan Y, Quan A et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295(4), H1377-H1384 (2008).
64. Dong B, Zhang C, Feng JB et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28(7), 1270-1276 (2008).
65. Thomas MC, Pickering RJ, Tsorotes D et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107(7), 888-897 (2010).
66. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, Ferrario CM. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J. Pharmacol. Exp. Ther. 265(2), 664-673 (1993).
67. Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 5(8), e12323 (2010).
68. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33(1 Pt 2), 207-211 (1999).
69. Langeveld B, Van Gilst WH, Tio RA, Zijlstra F, Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45(1), 138-141 (2005).
70. Zeng W, Chen W, Leng X, He JG, Ma H. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-b/Smad signaling pathway in rabbits. Biochem. Biophys. Res. Commun. 389(1), 138-144 (2009).
71. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 30(8), 1606-1613 (2010).
72. Sheng-Long C, Yan-Xin W, Yi-Yi H et al. AVE0991, a nonpeptide compound, attenuates angiotensin II-induced vascular smooth muscle cell proliferation via induction of heme oxygenase-1 and downregulation of p-38 MAPK phosphorylation. Int. J. Hypertens. 2012, 958298 (2012).
73. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27(3 Pt 2), 523-528 (1996).
74. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 46(4), 948-952 (2005).
75. Sampaio WO, Souza Dos Santos RA, Faria-Silva R, Da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49(1), 185-192 (2007).
76. Ray R, Murdoch CE, Wang M et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler. Thromb. Vasc. Biol. 31(6), 1368-1376 (2011).
77. Ferreira AJ, Shenoy V, Qi Y et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp. Physiol. 96(3), 287-294 (2011).
78. Ferreira AJ, Shenoy V, Yamazato Y et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am. J. Resp. Crit. Care 179(11), 1048-1054 (2009).
79. Fraga-Silva RA, Sorg BS, Wankhede M et al. ACE2 activation promotes antithrombotic activity. Mol. Med. 16(5-6), 210-215 (2010).
80. Zhong J, Basu R, Guo D et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122(7), 717-728 (2010).
81. Lula I, Denadai AL, Resende JM et al. Study of angiotensin-(1-7) vasoactive peptide and its b-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 28(11), 2199-2210 (2007).
82. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB et al. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo) 66(5), 837-841 (2011).
83. Marques FD, Ferreira AJ, Sinisterra RD et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 57(3), 477-483 (2011).
84. Marques FD, Melo MB, Souza LE et al. Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats. Int. J. Hypertens. 2012, 795452 (2012).
85. Kluskens LD, Nelemans SA, Rink R et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J. Pharmacol. Exp. Ther. 328(3), 849-854 (2009).
86. Durik M, Van Veghel R, Kuipers A et al. The effect of the thioether-bridged, stabilized angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int. J. Hypertens. 2012, 536426 (2012).
87. De Vries L, Reitzema-Klein CE, Meter-Arkema A et al. Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7). Peptides 31(5), 893-898 (2010).
88. Petty WJ, Miller AA, Mccoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin. Cancer Res. 15(23), 7398-7404 (2009).
89. Krishnan B, Torti FM, Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate doi:10. 1002/pros. 22540 (2012) (Epub ahead of print).
90. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol. Cancer Ther. 8(6), 1676-1683 (2009).
91. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 70(21), 8319-8328 (2010).
92. Rodgers K, Xiong SQ, Dizerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother. Pharmacol. 51(2), 97-106 (2003).
93. Rodgers KE, Xiong S, Dizerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother. Pharmacol. 49(5), 403-411 (2002).
94. Rodgers KE, Oliver J, Dizerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother. Pharmacol. 57(5), 559-568 (2006).
95. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc. Drug Rev. 24(3-4), 239-246 (2006).
96. Ebermann L, Spillmann F, Sidiropoulos M et al. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol. 590(1-3), 276-280 (2008).
97. Ferreira AJ, Oliveira TL, Castro ML et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci. 81(11), 916-923 (2007).
98. Carvalho MB, Duarte FV, Faria-Silva R et al. Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 50(4), 762-767 (2007).
99. Zeng WT, Chen WY, Leng XY et al. Impairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991. Cardiovasc. Ther. 30(3), 152-161 (2012).
100. Jawien J, Toton-Zuranska J, Gajda M et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J. Physiol. Pharmacol. 63(1), 77-85 (2012).
101. Singh K, Sharma K, Singh M, Sharma P. Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats. J. Renin Angiotensin Aldosterone Syst. 13(3), 334-340 (2012).
102. Shemesh R, Toporik A, Levine Z et al. Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J. Biol. Chem. 283(50), 34643-34649 (2008).
103. Savergnini SQ, Beiman M, Lautner RQ et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 56(1), 112-120 (2010).
104. Kaschina E, Grzesiak A, Li J et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118(24), 2523-2532 (2008).
105. Jehle AB, Xu Y, Dimaria JM et al. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J. Cardiovasc. Pharmacol. 59(4), 363-368 (2012).
106. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59(2), 291-299 (2012).
107. Paulis L, Becker ST, Lucht K et al. Direct angiotensin II type 2 receptor stimulation in Nomega-nitro-l-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 59(2), 485-492 (2012).
108. Abdalla S, Abdel-Baset A, Lother H, el Massiery A, Quitterer U. Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J. Mol. Neurosci. 26(2-3), 185-192 (2005).
109. Barki-Harrington L. Oligomerisation of angiotensin receptors: novel aspects in disease and drug therapy. J. Renin Angiotensin Aldosterone Syst. 5(2), 49-52 (2004).
110. Zeng C, Yang Z, Wang Z et al. Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells. Hypertension 45(4), 804-810 (2005).
111. Rozenfeld R, Gupta A, Gagnidze K et al. AT1R-CB(1)R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30(12), 2350-2363 (2011).
112. Kostenis E, Milligan G, Christopoulos A et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111(14), 1806-1813 (2005).
113. Canals M, Jenkins L, Kellett E, Milligan G. Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of G(q)/G(11) by MAS. J. Biol. Chem. 281(24), 16757-16767 (2006).
114. Abdalla S, Lother H, Abdel-Tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 276(43), 39721-39726 (2001).
115. Siddiquee K, Hampton J, Mcanally D, May LT, Smith LH. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br. J. Pharmacol. (2012).
116. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am. J. Physiol. Heart Circ. Physiol. 294(5), H2242-H2247 (2008).
117. Kemp BA, Bell JF, Rottkamp DM et al. Intrarenal Angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension 60(2), 387-395 (2012).